Acute Myeloid Leukaemia (AML)

Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia

In a randomized phase 2 trial (172 adults with previously untreated acute myeloid leukaemia who were fit for intensive treatment), azacitidine plus venetoclax extended median event-free survival to 14.5 months versus 6.2 months with induction chemotherapy (HR 0.57; p=0.0021) at a median follow-up of…